This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ristau BT , Chen DYT , Ellis J , Malhotra A , DeMora L , Parsons RB , Milestone B , Brody M , Viterbo R , Greenberg R , Smaldone M , Uzzo R , Anaokar J , Kutikov A
Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy
J Urol. 2018 Apr;199(4) :969-975
PMID: 28988963 PMCID: PMC7603901 URL: https://www.ncbi.nlm.nih.gov/pubmed/28988963
AbstractPURPOSE: Multiparametric magnetic resonance (mpMRI)/ultrasound targeted prostate biopsy (TB) is touted as a tool to improve prostate cancer care. Yet, the true clinical utility of TB over transrectal ultrasound-guided prostate biopsy (TRUS-B) has not been systematically analyzed. We introduce two metrics to better quantify and report the deliverables of TB. MATERIALS AND METHODS: We reviewed our prospective database containing patients who underwent simultaneous TB/TRUS-B. Actionable Intelligence Metric (AIM) was defined as the proportion of patients for whom TB provided actionable information over TRUS-B. Reduction Metric (ReM) was defined as the proportion of men in whom TRUS-B could have been omitted. We compared metrics within our cohort and prior reports. RESULTS: 371 men were included. AIM and ReM were 22.2% and 83.6% for biopsy naive, 26.7% and 84.2% for prior negative TRUS-B, and 24% and 77.5% for active surveillance patients. No significant differences among groups were observed (p = 0.89 for AIM; p = 0.27 for ReM). AIM was 25.0% for PIRADS 3, 27.5% for PIRADS 4 and 21.7% for PIRADS 5 (p = 0.73) lesions. TRUS-B could have been avoided in more patients with PIRADS 3 compared to PIRADS 4/5 lesions (ReM 92.0% vs. 76.7%, p < 0.01). Our results compare favorably to other reported series. CONCLUSIONS: AIM and ReM are novel, clinically relevant quantification metrics to standardize reporting of TB deliverables. TB affords actionable information (AIM) in approximately 25% of men. ReM assessment highlights that TRUS-B may only be omitted after carefully considering the risk of missing clinically significant cancers.
Notes1527-3792 Ristau, Benjamin T Chen, David Y T Ellis, Jeffrey Malhotra, Aseem DeMora, Lyudmilla Parsons, Rosaleen B Milestone, Barton Brody, Marion Viterbo, Rosalia Greenberg, Richard Smaldone, Marc Uzzo, Robert Anaokar, Jordan Kutikov, Alexander Journal Article United States J Urol. 2018 Apr;199(4):969-975. doi: 10.1016/j.juro.2017.09.124. Epub 2017 Oct 6.